How safe are GLP-1 drugs when used for weight loss?

Dr. Zeina Habib is an endocrinologist and an internal medicine faculty member at Central Michigan University’s medical school. She is a board‑certified endocrinologist who manages a broad range of endocrine conditions, including diabetes, bone and metabolic disorders, obesity and thyroid disease.

Key takeaways

• Nausea, vomiting, diarrhea and constipation are the most common side effects
• No evidence directly ties GLP-1 drugs to issues with the pancreas
• Use of GLP-1 drugs can lead to loss of bone density, especially with bigger weight loss

Q. What are the most common side effects of GLP‑1 drugs like Ozempic, Wegovy and Mounjaro?

The most common side effects of GLP‑1 drugs are gastrointestinal (GI) symptoms such as nausea (the most common), vomiting, diarrhea and constipation. These occur because one of the ways GLP‑1 medications work is by slowing stomach emptying and gut motility. When stomach emptying is slower, people feel full sooner and stay full longer, so they eat smaller portions and absorb less glucose, effects that support weight loss and diabetes control. But this same mechanism is also responsible for the GI side effects many patients experience.

These side effects are most noticeable when starting GLP‑1s or when increasing the dose, but they usually improve over time. This is why it’s important to begin with a low dose and make sure it is well tolerated before moving to the next one. Doses can be increased every four weeks, though sometimes we need to go slower if side effects occur. In some cases, we may need to stop the medication altogether if symptoms are severe, allow time for recovery, and then try again later or switch to a different agent if appropriate. Caution is recommended in individuals with a history of gastroparesis, who already have slower stomach emptying at baseline, as GLP‑1s may trigger or worsen symptoms.

For people starting these medications, we usually recommend reducing portion sizes upfront, since the stomach may not tolerate the same amount of food with slower emptying. This can help mitigate some of the GI symptoms. We also talk about choosing nutrient‑dense foods to ensure adequate nutrition with smaller portions. In addition, we recommend avoiding foods that are known to cause stomach upset in that individual, as these may have a more prolonged effect when they remain in the stomach for a longer period of time.

Q. Do GLP‑1 drugs increase the risk of serious conditions such as pancreatitis, gallbladder disease or kidney injury?

There is no strong evidence that GLP‑1 drugs increase the risk of acute pancreatitis. Although a few observational studies have suggested a potentially higher risk in GLP‑1 users compared to non‑users, more rigorous research and large‑scale real‑world data have been reassuring. However, GLP‑1 clinical trials generally exclude patients with a history of pancreatitis, and we tend to do the same in real‑world practice. For that reason, their use in individuals with a prior episode of pancreatitis is generally not recommended, and they should be discontinued in anyone who develops pancreatitis while taking a GLP‑1 medication.

The increased risk of gallbladder disease or gallbladder stones with GLP‑1 drugs is more well established. The risk, although relatively small, stems from both slowing of gallbladder emptying and rapid weight loss, which is known to promote gallbladder stone formation. The presence of stones is not necessarily a contraindication to therapy, but any new abdominal pain in a patient taking a GLP‑1 should be evaluated promptly, as these medications may increase the risk of acute gallbladder inflammation requiring surgery. In these cases, restarting GLP‑1 therapy after surgery can be considered and is not absolutely contraindicated.

As for kidney injury, acute kidney injury has been reported with GLP‑1 drugs, but it is mostly related to dehydration in patients experiencing severe nausea, vomiting or diarrhea, rather than a direct effect of the medication itself. In fact, when looking at long‑term outcomes, GLP‑1 drugs have been shown to be kidney‑protective. For patients experiencing significant gastrointestinal side effects, maintaining good hydration and temporarily holding or reducing the dose until symptoms improve can help reduce the risk of acute kidney injury.

Q. Are GLP‑1 medications safe for people with thyroid issues or a family history of thyroid cancer?

Yes, GLP‑1 medications are generally safe to use in people with thyroid disorders or thyroid cancer, with the exception of a very specific type of thyroid cancer called medullary thyroid cancer, which starts in specialized cells in the thyroid gland known as C‑cells. So, if a person has a personal or family history of medullary thyroid cancer, or a genetic condition called multiple endocrine neoplasia type 2 (MEN2), which carries a higher risk of medullary thyroid cancer, the use of GLP‑1 drugs is generally contraindicated.

That being said, it is important to know that GLP‑1 medications have not been associated with a higher risk of medullary thyroid cancer in humans based on available research. In early rodent studies, these medications stimulated C‑cells to multiply and, in some cases, become cancerous. That is the basis for the warning on the drug labels. However, human thyroids are different from rodent thyroids and may not respond to GLP‑1 drugs in the same way. So the findings in rodents may not necessarily apply to humans, and research is ongoing.

In clinic, when prescribing GLP‑1 medications, we routinely screen for any personal or family history of medullary thyroid cancer or MEN2, both of which are rare, and we make sure to properly evaluate any thyroid nodules or lumps according to current standards of practice. But overall, the number of patients who have a thyroid‑related contraindication to GLP‑1 use is very small.

Q. Do GLP‑1 drugs affect bone density, fracture risk, or long‑term musculoskeletal health?

The research on the effects of GLP‑1 drugs on bone is still evolving. Early studies in cells and animals suggest these medications may promote new bone formation. However, in real‑world use, GLP‑1 drugs have been associated with a decrease in bone density in people taking them for diabetes or obesity management. In fact, the more weight that is lost, the more pronounced the bone loss tends to be.

When it comes to fracture risk, there is no strong evidence at this time that GLP‑1 drugs increase the risk of fragility fractures. This may simply reflect the timeline: bone loss appears first, fractures occur later, and current studies may not have followed patients long enough to detect a difference. Another possibility is that fracture risk truly does not increase, and the bone loss represents mechanical unloading, meaning the skeleton is adjusting to a lower body weight, while bone quality remains stable or even improves due to the bone‑forming effects seen in early research.

Loss of muscle mass is another concern with GLP‑1 drugs, and it appears to be unavoidable. Roughly one quarter to one third of the weight lost with these medications is lean muscle, with the exact amount depending on how much weight is lost and how quickly. This does not necessarily mean strength or physical function will decline, but it can be more significant in individuals who are older, less active, or not consuming adequate protein, situations where problems are more likely to arise.

To help preserve bone density, muscle mass and strength while on GLP-1 drugs, it is important to engage in weight‑bearing and resistance exercises, maintain good nutrition with adequate protein intake and avoid excessively rapid weight loss.

Q. What long‑term health risks or unknowns remain for chronic GLP‑1 use, especially for weight loss?

What we know so far about GLP‑1 drugs when used for weight management is that, in addition to their powerful weight‑loss benefit, they can reduce the risk of heart, kidney and liver complications, and lead to improvement in obstructive sleep apnea and knee osteoarthritis. When used for diabetes, they not only improve glucose control and support weight loss but also reduce the risk of death; lower the risk of cardiovascular events such as heart attacks, strokes, and cardiac deaths; decrease the risk of heart‑failure hospitalization; and slow the progression of diabetic kidney disease.

The long‑term safety profile of these medications, when used properly and with close observation, appears to be favorable. GLP‑1s have been around for over 20 years, though the earlier drugs were twice‑daily and daily agents that did not have the significant weight‑loss effects we see today. Their benefits largely outweigh the risks, but there are a few conditions we need to keep in mind. We talked earlier about gastrointestinal side effects, pancreatitis, gallbladder disease, thyroid cancer and effects on the musculoskeletal system.

Other concerns include the possibility of worsening retinopathy, or diabetic eye disease, mostly seen in individuals who already have retinopathy and experience a rapid improvement in glucose levels. It is important to evaluate for retinopathy prior to initiating these medications in individuals with uncontrolled diabetes. There is also an increased risk of hypoglycemia when GLP‑1 drugs are added to insulin or sulfonylureas, and those medications may need to be adjusted when initiating or escalating GLP‑1 therapy. Risk of aspiration from retained stomach content is another described risk in patients undergoing surgery or general anesthesia, so these drugs should be held in patients at risk ahead of upcoming surgery.

GLP‑1 medications are now commonly used, and their uptake has grown rapidly over the past few years. As more people use these drugs, new research continues to emerge about their long‑term safety. Current evidence is reassuring overall, but it will be important to keep watching the data as it evolves.

About Dr. Zeina Habib

Dr. Zeina Habib is a board‑certified endocrinologist who manages a broad range of endocrine conditions, including diabetes, bone and metabolic disorders, obesity and thyroid disease.

Her special interests include diabetes prevention and improving community health literacy as it relates to diabetes. Dr. Habib has been actively involved in community education, participating in multiple outreach events focused on early detection, lifestyle modification and risk‑reduction strategies. Her research spans several areas within endocrinology, including the side effects of diabetes medications, bone and mineral disorders and thyroid hormone replacement, contributing important insights to the field. She brings a strong blend of clinical expertise, public‑health engagement and research experience to advancing high‑quality, patient‑centered endocrine care.